GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. And as of December 20, Eli Lilly’s weight loss ...

The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...

Zepbound, a drug that rivals Ozempic, may one day be a treatment for sleep apnea, according to results from a new study. Jessica was a writer on the Wellness team, with a focus on health technology, ...

April 17 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped reduce episodes of irregular breathing associated with a common sleep-related disorder in two ...

The diabetes and weight loss drug tirzepatide appears to help people with obesity who also have sleep apnea, according to preliminary findings from drugmaker Eli Lilly. The results, while unpublished, ...

New research showed that tirzepatide, the compound in Zepbound, improved symptoms of obstructive sleep apnea. By Dani Blum Reporting from the American Diabetes Association conference in Orlando, Fla.

Standard treatment for breathing problems caused by obstructive sleep apnea is a medical device. But many people find it uncomfortable to wear the mask that comes with a continuous positive airway ...